PHOENIX — Prescribing Qlosi eye drops for presbyopia was not associated with a reduction in optical purchases or other practice performance metrics, according to a study presented here.
“The questions that kept coming up among our physicians were straightforward: Is this going to hurt us? Are patients going to stop buying glasses? Are we going to see fewer billable encounters?” Harmin J. Chima, OD, FAAO, vice president, professional services at West Point Optical Group, told Healio. “Those are legitimate questions, and nobody had real answers yet.”
Orasis Pharmaceuticals worked with West Point
— Curated from external eye-care sources for opthametry.com readers.
📰 Original Source: Healio Optometry
Discover more from An Eye Care Blog
Subscribe to get the latest posts sent to your email.
